RegulatoryOfficial
EMA extends 2026/2027 flu vaccine composition advice to mRNA influenza vaccines
🇪🇺 EMA · Tue 17 Nov 2026
The EU regulator's 17 November update adds a recommendation for nucleic acid-based flu vaccines and revises Annex I on reagents for vaccine standardisation.
The European Medicines Agency (EMA) updated its EU recommendations for the composition of 2026/2027 seasonal influenza vaccines on 17 November 2026. The revision adds a recommendation for mRNA (nucleic acid) influenza vaccines. Annex I, which covers reagents for vaccine standardisation, was also updated.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (EMA). AI-assisted; check the source before acting.
More Regulatory
All →
EEA Joint Committee extends three EU feed additive rules to Iceland and Norway
🇪🇺 EUR-Lex · Thu 19 Nov 2026
Health Canada lists Class II recall of Stryker's Blueprint shoulder-planning software over two bugs
🇨🇦 Health Canada · Wed 18 Nov 2026
FDA approves Infilbray, first treatment for neurological symptoms of Type 3 Gaucher disease
🇺🇸 FDA · Wed 18 Nov 2026
INFARMED lifts suspension of Limeciclina Atral 408 mg capsules after bioequivalence shown
🇵🇹 INFARMED · Wed 18 Nov 2026
Commission publishes minutes of SCHEER working group meeting on brain stimulators
🇪🇺 European Commission (DG SANTE) · Wed 18 Nov 2026
AIFA reminds sponsors how to pay Annual Safety Report evaluation fee
🇮🇹 AIFA · Wed 18 Nov 2026